Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Liabilities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Total Liabilities for 14 consecutive years, with $29.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 34.66% to $29.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.9 million, a 34.66% increase, with the full-year FY2025 number at $29.9 million, up 34.66% from a year prior.
  • Total Liabilities was $29.9 million for Q4 2025 at Niagen Bioscience, up from $27.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $29.9 million in Q4 2025 to a low of -$43.8 million in Q1 2021.
  • A 5-year average of $22.1 million and a median of $25.8 million in 2022 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 228.31% in 2021; the steepest drop was 329.94% in 2021.
  • Niagen Bioscience's Total Liabilities stood at $26.1 million in 2021, then dropped by 2.79% to $25.4 million in 2022, then rose by 4.42% to $26.5 million in 2023, then dropped by 16.31% to $22.2 million in 2024, then soared by 34.66% to $29.9 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Total Liabilities are $29.9 million (Q4 2025), $27.5 million (Q3 2025), and $27.3 million (Q2 2025).